Day: June 27, 2024

Not for distribution to U.S. newswire services or for dissemination in the United States MISSISSAUGA, Ontario, June 27, 2024 (GLOBE NEWSWIRE) — Chartwell Retirement Residences (TSX:CSH.UN) (“Chartwell”) announced the closing of its previously announced public offering (the “Offering”) of 28,290,000 of trust units (“Trust Units”), inclusive of 3,690,000 Trust Units issued pursuant to the exercise in full of the over-allotment option, at a price of $12.20 per Trust Unit for total gross proceeds of approximately $345 million. The Offering was completed on a bought deal basis through a syndicate of investment dealers led by TD Securities Inc., Scotiabank and RBC Capital Markets. The Trust Units were offered in each of the provinces of Canada pursuant to a prospectus supplement dated June 24, 2024 (the “Prospectus Supplement”) filed...

CHATHAM, N.J., June 27, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced it has entered into a placement agency agreement for the purchase and sale of approximately 7,060,918 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.57 per share (or $0.569 per pre-funded warrant in lieu thereof). The closing of the public offering is expected to take place on or about June 28, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds of the offering will be approximately $4.0 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working...

Data demonstrates improvement in cognitive function in GBA1 Parkinson’s disease model in addition to reversal of motor function deficits BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the presentation of a poster at the Federation of European Neuroscience Societies (FENS) Forum 2024. The poster describes improvement in cognitive performance and activities of daily living associated with administration of GT-02287 the Company’s lead novel allosteric therapeutic candidate in a mouse model of GBA1-Parkinson’s disease (GBA1-PD). FENS Forum 2024 is being held June 25–29, 2024 in Vienna, Austria. “These data...

Seeing Accelerated Revenue Growth from Current and New Opportunities Miami, FL, June 27, 2024 (GLOBE NEWSWIRE) — Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”) (NASDAQ: BSFC), an integrated Environmental, Social, and Governance (ESG) sustainable seafood company with a focus on Recirculatory Aquaculture Systems (RAS), is pleased to announce that it is providing a 2024 forecast of at least 65% revenue growth with an annual run-rate of greater than $20 million. The Company has been successful in securing new business for growth opportunities for the future, such as an increased customer base at its Canadian facility for steelhead salmon. “We are excited to showcase our commitment to company growth in 2024. Our actionable plan started to show in our financial and operating results, as reflected in our recently...

VANCOUVER, British Columbia, June 27, 2024 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE:VERS) (OTCQB:VRSSF) (“VERSES” or the “Company”), a cognitive computing company developing next-generation intelligent software systems, today announced that on Wednesday July 3, 2024 at 1:00PM ET, CEO Gabriel René will provide a corporate update on recent events and strategic plans. On the Webinar Mr. René will address:State of the AI Industry The Recent Strategic Investment from G42 The Launch and Rollout of the Genius Platform Update on AI Benchmarks Status of Spatial Web Protocol, Architecture and Governance StandardsTo register for the webinar interested parties can use the following link: https://event.webinarjam.com/register/323/onqrlty7 To learn more about Genius, please visit: https://www.verses.ai/genius Developers can sign up for Genius...

Selangor, Malaysia, June 27, 2024 (GLOBE NEWSWIRE) — ARB IOT Group Limited (“ARB” or the “Company”) (NASDAQ: ARBB), a provider of complete solutions to clients for the integration of Internet of Things (“IoT”) systems and devices from designing to project deployment, today announced that on June 25, 2024, it received a written notification letter (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of US$1.00 per share. Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive...

Company Becomes “Official Performance Partner” For Men’s and Women’s Teams and co-title partner on the women’s team, now riding as “EF-Oatly-Cannondale”Oatly Announces Partnership with EF Pro CyclingCompany Becomes “Official Performance Partner” For Men’s and Women’s Teams and co-title partner on the women’s team, now riding as “EF-Oatly-Cannondale”Oatly Announces Partnership with EF Pro CyclingCompany Becomes “Official Performance Partner” For Men’s and Women’s Teams and co-title partner on the women’s team, now riding as “EF-Oatly-Cannondale”MALMÖ, Sweden, June 27, 2024 (GLOBE NEWSWIRE) — Oatly, the world’s original and largest oatmilk company, today announced it has entered into a multi-year sponsorship of EF Pro Cycling, one of the world’s most prestigious professional cycling organizations and the longest...

VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC Laboratories, Inc. (“SMC”) has commenced, with results expected in the fall of 2024. CytoDyn believes its prior MASH study demonstrated a statistically significant benefit of leronlimab at a dosing level of 350 mg. To clarify the optimal dosing and evaluate the potential for combination therapy, SMC will be conducting a twelve-week preclinical mouse study evaluating both 350 and 700 mg dose levels, alone and in combination with Resmetirom, a drug recently approved by the FDA. The study will evaluate leronlimab’s potential...

ROUND ROCK, Texas, June 27, 2024 (GLOBE NEWSWIRE) — Total Site Solutions (OTC: TSSI), a leader in end-to-end integration technology solutions for data centers and modular services, announced today the promotion of Todd Marrott to Chief Operating Officer (COO), effective July 1, 2024. Marrott joined TSS as the Senior Vice President of Operations in November 2022, bringing a wealth of experience and expertise that has since driven significant improvements across the organization. “Todd’s dynamic leadership style and deep operational expertise have had a huge impact on TSS,” said Darryll Dewan, Total Site Solutions CEO and President. “He has spearheaded a comprehensive overhaul of TSS’s Systems Integration business line, returning this business to operating profitability while driving planning and execution of significant enhancements...

Leading women’s reproductive health conference directly follows the company’s EU CE Mark approval for four of its products ATLANTA, June 27, 2024 (GLOBE NEWSWIRE) — Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces it will be participating at the European Society of Human Reproduction and Embryology’s (ESHRE) 40th Annual Meeting in Amsterdam on July 7-10. The Company will be exhibiting at booth #11,111. The conference follows Femasys receiving CE Mark certification for four of its products – FemaSeed®, FemVue®, FemCerv®, and FemCath® – making them compliant with the new European Union legislation for medical devices and approved for commercial sale. “This...